Abstract
Background. The prevention of oral mucositis (OM) in the management of hematological malignancies continues to represent an unmet clinical need. Addressing this issue has major clinical implications as OM can also greatly impair patient’s quality of life. Objectives. To review currently available measures and investigational agents to prevent OM in hematological patients. Methods: we searched for OM and related issues using Medline; the abstract books of the most important hematological and oncological meetings were also reviewed. Results/Conclusions. Many agents targeting different mechanisms of mucosal damage have been applied in order to prevent OM; most of them have failed or its efficacy has not been fully demonstrated. Palifermin is the first pharmaceutical/biological agent approved for the prevention of OM; its use is currently restricted to patients who have received radiotherapy-containing conditioning regimens prior to autologous hematopoietic stem cell transplantation. No clear benefit by this agent has been demonstrated outside of this specific setting and its application should be limited to clinical trials. Other interventions, such as other growth factors and non mitogenic measures are under investigation or in development and their application in the hematological setting is expected in the short term.
Keywords: Antineoplastic treatments, chemotherapy, hematology, hematopoietic stem cell transplantation, Lactobacillus brevis CD2, leukemia, lymphoma, multiple myeloma, mucositis, oral cavity, palifermin, prevention, radiotherapy, stomatitis
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:The Prevention of Oral Mucositis in Patients with Blood Cancers: Current Concepts and Emerging Landscapes
Volume: 10 Issue: 4
Author(s): Pasquale Niscola, Andrea Tendas, Luca Cupelli, Gianfranco Catalano, Laura Scaramucci, Marco Giovannini, Vito Trinchieri, Atul Sharma, Fabio Efficace, Claudio Cartoni, Daniela Piccioni, Alessio Perrotti, Teresa Dentamaro, Paolo de Fabritiis and Dorothy M.K. Keefe
Affiliation:
Keywords: Antineoplastic treatments, chemotherapy, hematology, hematopoietic stem cell transplantation, Lactobacillus brevis CD2, leukemia, lymphoma, multiple myeloma, mucositis, oral cavity, palifermin, prevention, radiotherapy, stomatitis
Abstract: Background. The prevention of oral mucositis (OM) in the management of hematological malignancies continues to represent an unmet clinical need. Addressing this issue has major clinical implications as OM can also greatly impair patient’s quality of life. Objectives. To review currently available measures and investigational agents to prevent OM in hematological patients. Methods: we searched for OM and related issues using Medline; the abstract books of the most important hematological and oncological meetings were also reviewed. Results/Conclusions. Many agents targeting different mechanisms of mucosal damage have been applied in order to prevent OM; most of them have failed or its efficacy has not been fully demonstrated. Palifermin is the first pharmaceutical/biological agent approved for the prevention of OM; its use is currently restricted to patients who have received radiotherapy-containing conditioning regimens prior to autologous hematopoietic stem cell transplantation. No clear benefit by this agent has been demonstrated outside of this specific setting and its application should be limited to clinical trials. Other interventions, such as other growth factors and non mitogenic measures are under investigation or in development and their application in the hematological setting is expected in the short term.
Export Options
About this article
Cite this article as:
Niscola Pasquale, Tendas Andrea, Cupelli Luca, Catalano Gianfranco, Scaramucci Laura, Giovannini Marco, Trinchieri Vito, Sharma Atul, Efficace Fabio, Cartoni Claudio, Piccioni Daniela, Perrotti Alessio, Dentamaro Teresa, de Fabritiis Paolo and M.K. Keefe Dorothy, The Prevention of Oral Mucositis in Patients with Blood Cancers: Current Concepts and Emerging Landscapes, Cardiovascular & Hematological Agents in Medicinal Chemistry 2012; 10 (4) . https://dx.doi.org/10.2174/187152512803530324
DOI https://dx.doi.org/10.2174/187152512803530324 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biosafety of Adenoviral Vectors
Current Gene Therapy Targeting Cancer Cells with Photoactive Silica Nanoparticles
Current Pharmaceutical Design Emerging Roles of P2X Receptors in Cancer
Current Medicinal Chemistry Regulatory T Cell Counts and Development of Malignancy in Patients with HIV Infection
Current HIV Research B-lymphocytes as Targets for Therapy in Chronic Cold Agglutinin Disease
Cardiovascular & Hematological Disorders-Drug Targets Heat Shock Protein 90 – a Potential Target in the Treatment of Human Acute Myelogenous Leukemia
Current Cancer Drug Targets Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia
Current Cancer Drug Targets Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Regulation of Platelet Function by Acetylation/Deacetylation Mechanisms
Current Medicinal Chemistry Potential of Selected Indian Herbs for COVID-19
Current Traditional Medicine Heparin Induced Thrombocytopenia: Pathogenetic, Clinical, Diagnostic and Therapeutic Aspects
Cardiovascular & Hematological Disorders-Drug Targets Interferons: Mechanisms, Biological Activities and Survey of their Use in Human Diseases
Current Bioactive Compounds Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Current Drug Targets Marine Derived Anticancer Drugs Targeting Microtubule
Recent Patents on Anti-Cancer Drug Discovery Genes that Modulate the Sensitivity for Anti-Microtubule Drug-Mediated Chemotherapy
Current Cancer Drug Targets Major Challenges for Gene Therapy of Thalassemia and Sickle Cell Disease
Current Gene Therapy Oral and Dental Considerations in the Management of Leukemic Children
Applied Clinical Research, Clinical Trials and Regulatory Affairs HIV-Related Lymphoproliferative Diseases in the Era of Combination Antiretroviral Therapy
Cardiovascular & Hematological Disorders-Drug Targets Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities
Current Drug Targets Telomerase as a Cancer Target. Development of New Molecules
Current Topics in Medicinal Chemistry